Rhumbline Advisers Increases Stake in Neurogene Rhumbline Advisers boosted its holdings in Neurogene Inc. by 9.2% during Q4, acquiring 1,326 additional shares. The firm now owns 15,704 shares, valued at approximately $359,000. This move reflects growing institutional interest in Neurogene, a biotechnology company specializing in genetic treatments for rare neurological diseases.1